By Joseph Harvey
January 26, 2017
Elanco has addressed a significant unmet need in the US by making Galliprant available for the control of pain and inflammation associated with canine osteoarthritis (OA).
The product, developed through to US approval by Aratana Therapeutics, is now available to veterinarians for once-daily use in dogs with OA. The tablets can be used in dogs as young as nine months old and weighing eight pounds or more. Aratana said most dogs can be dosed once a day with a whole or half tablet.
Elanco has exclusive rights to develop, manufacture and market Galliprant (grapiprant tablets) globally, and the firm also co-promotes the product with Aratana in the US. The two companies came together as part of a landmark agreement last year.
Galliprant was Aratana's debut US approval in March 2016. It is the first piprant – a non-cyclooxygenase-inhibiting prostaglandin receptor antagonist – approved for use in veterinary medicine. The product adds to Elanco's osteoarthritis offering, which also features the Onsior treatment.
Dr Tony Rumschlag, director of regional consulting veterinarians for Elanco, said: "It is estimated one in five dogs is affected by osteoarthritis. Large breeds, such as the popular retriever breeds, as well as overweight dogs, are especially prone.
"Early diagnosis and intervention to control pain and inflammation can help give arthritic dogs improved quality of life. With Galliprant, we have a medication that provides targeted pain relief from the earliest diagnosis of canine OA, while reducing the impact on gastrointestinal, kidney and liver homeostasis."
According to Aratana, Galliprant represents "an important innovation in the evolution of canine anti-inflammatory drugs because it targets the clinical signs by specifically blocking the prostaglandin EP4 receptor, which is the primary mediator of OA pain and inflammation".
However, the product does not inhibit the production of many prostanoids that maintain the dog's homeostatic functions.
While Galliprant was Aratana's first approval, the company launched Nocita (bupivacaine liposome injectable suspension) on the US market last October.
Reprinted with permission of Animal Pharm News